Sabra Health Care REIT upgraded by Citigroup with a new price target
$SBRA
Real Estate Investment Trusts
Real Estate
Citigroup upgraded Sabra Health Care REIT from Neutral to Buy and set a new price target of $20.00 from $17.00 previously
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/17/2025 | Buy → Hold | Truist | |
1/7/2025 | $20.00 | Mkt Perform → Mkt Outperform | JMP Securities |
12/5/2024 | $20.00 | Outperform → Neutral | Mizuho |
10/1/2024 | $16.00 → $20.00 | Equal Weight → Overweight | Wells Fargo |
9/13/2024 | $17.00 → $20.00 | Neutral → Buy | Citigroup |
1/30/2024 | $21.00 | Buy | Deutsche Bank |
10/17/2023 | $16.00 | Outperform → Market Perform | BMO Capital Markets |
10/16/2023 | $13.00 → $15.00 | Underweight → Equal Weight | Wells Fargo |
4 - Sabra Health Care REIT, Inc. (0001492298) (Issuer)
4 - Sabra Health Care REIT, Inc. (0001492298) (Issuer)
4 - Sabra Health Care REIT, Inc. (0001492298) (Issuer)
4 - Sabra Health Care REIT, Inc. (0001492298) (Issuer)
4 - Sabra Health Care REIT, Inc. (0001492298) (Issuer)
Truist downgraded Sabra Health Care REIT from Buy to Hold
JMP Securities upgraded Sabra Health Care REIT from Mkt Perform to Mkt Outperform and set a new price target of $20.00
Mizuho downgraded Sabra Health Care REIT from Outperform to Neutral and set a new price target of $20.00